key: cord-1040011-y99ngrwn
authors: Katsonis, Panagiotis; Wilhelm, Kevin; Williams, Amanda; Lichtarge, Olivier
title: Genome interpretation using in silico predictors of variant impact
date: 2022-04-30
journal: Hum Genet
DOI: 10.1007/s00439-022-02457-6
sha: d2ab2995095d1b6c1d746d0aa6c07fa5149f66f4
doc_id: 1040011
cord_uid: y99ngrwn

Estimating the effects of variants found in disease driver genes opens the door to personalized therapeutic opportunities. Clinical associations and laboratory experiments can only characterize a tiny fraction of all the available variants, leaving the majority as variants of unknown significance (VUS). In silico methods bridge this gap by providing instant estimates on a large scale, most often based on the numerous genetic differences between species. Despite concerns that these methods may lack reliability in individual subjects, their numerous practical applications over cohorts suggest they are already helpful and have a role to play in genome interpretation when used at the proper scale and context. In this review, we aim to gain insights into the training and validation of these variant effect predicting methods and illustrate representative types of experimental and clinical applications. Objective performance assessments using various datasets that are not yet published indicate the strengths and limitations of each method. These show that cautious use of in silico variant impact predictors is essential for addressing genome interpretation challenges.

The drastic reduction in the cost of genome sequencing over the last decade (DNA Sequencing Costs: Data 2020) led to a proliferation of large-scale next-generation sequencing (NGS) datasets (Pereira et al. 2020) . The NCBI dbGaP database (Mailman et al. 2007 ) hosts a vast collection of genotype-phenotype data in a common repository, but many other data sets of broad interest reside elsewhere and not all have simple access (Gutierrez-Sacristan et al. 2021) . Currently, dbGaP contains more than 500 NGS case-control studies, including studies of such diseases as Alzheimer's (Beecham et al. 2017 ), Parkinson's (Rosenthal et al. 2016) , autism spectrum disorder (ASD) (Fischbach and Lord 2010), and others (Taliun et al. 2021) . Additional case-control studies on the same or similar traits are available through other independent initiatives (Marek et al. 2018; Petersen et al. 2010) . Other sources, called biobanks, contain sequencing data and clinical diagnostics from individuals representing a population, without a focus on any particular disease. Examples include the UK Biobank, which currently holds genetic data from about 500,000 individuals (Backman et al. 2021; Bycroft et al. 2018) , as well as the All of Us Research Program (All of Us Research Program et al. 2019) among others (Wichmann et al. 2011) . Some datasets focus on ethnic differences, such as The 1000 Genomes Project (The 1000 Genomes Project Consortium 2015) and various population-specific cohorts (Genome of the Netherlands Consortium 2014; Jeon et al. 2020; Kim et al. 2018; Nagasaki et al. 2015) . Each of these sources contains rich data on human genetic variations over which we can address questions of disease etiology for mechanistic understanding, risk for prevention and early screening, personalized therapy for precision medicine, epistatic effects for complex epidemiology, pharmacogenomics for patient stratification, and ethnic diversity for health equity. Accurate metrics for the impact of individual variants is critical to guide answers to these questions.

There are many types of genetic variants, broadly grouped by the region in which the variant occurs and the number of nucleotides affected. Variants can occur in protein coding regions or non-coding regions of the genome. Although the protein coding region represents only 1.2% of the human genome (Encode Project Consortium 2012), past variant interpretation efforts focused on these variants due to their effects in protein synthesis. However, a large proportion of the non-coding genome is functional and harbors variants that drive diseases by influencing regulatory regions controlling gene expression and untranslated regions affecting mRNA translation (French and Edwards 2020). Variants can also encompass single or multiple nucleotides. Substitutions that add or remove nucleotides are called insertions or deletions, respectively, and they are rare compared to single nucleotide variants (SNVs) that account for about 90% of the variants (1000 Genomes Project Consortium et al. 2010) . Protein coding insertion and deletion (indel) variants may be pathogenic when they shift the reading frame of mRNA or map to functionally important sites Mullaney et al. 2010) . Protein coding SNVs may truncate the protein (stop gain and start loss), cause no change to the protein sequence (synonymous), or alter one amino acid (non-synonymous/missense). Stop gain and start loss variants exert profound effects on protein function, resulting in strong selection against them (Bartha et al. 2015) . Synonymous variants are assumed to be benign, although they can cause various pre-translational changes (Zeng and Bromberg 2019) and affect codon usage bias (Plotkin and Kudla 2011) . The impact of non-synonymous variants is challenging to predict, since they may affect a number of protein characteristics, such as folding (Wang and Moult 2001) , protein interactions (Teng et al. 2009 ), dynamics (Uversky et al. 2008) , post-translational modifications (Yang et al. 2019) , solubility (Monplaisir et al. 1986) , and others (Stefl et al. 2013) , with approximately 30% of variants having a strong impact (Chasman and Adams 2001) . Purifying selection accounts for all the above effects and reduces diversity within species (Cvijovic et al. 2018) , allowing only beneficial and nearly neutral variants to spread and become fixed (Fu and Akey 2013; Patwa and Wahl 2008) . Assuming the variant effects differ little between homologous proteins, the genetic differences between the species offer valuable information for estimating the overall effect of a variant (Ng and Henikoff 2001) . The 3D structures of proteins can also provide additional complementary insights (Orengo et al. 1999; Ramensky et al. 2002) . Consequently, homology and structure information have been the two main types of input for estimating the effects of coding variants on protein function.

Many computational methods estimate variant effects ), but their aims may differ. Some methods focus on specific aspects of protein function, such as folding stability of the mutated protein (Capriotti et al. 2005 (Capriotti et al. , 2008 Cheng et al. 2006; Dehouck et al. 2011; Fariselli et al. 2015; Guerois et al. 2002; Parthiban et al. 2006; Pires et al. 2014; Quan et al. 2016; Worth et al. 2011; Zhou and Zhou 2002) or a combination of folding stability and binding affinity (Berliner et al. 2014) . Typically, these folding prediction methods estimate the free energy change of folding (∆∆G) due to mutation from 3D structures in addition to scores derived from different forcefields or evolutionary information. Encouragingly, about three-fourths of variants that cause Mendelian disorders affect protein stability (Wang and Moult 2001; Yue et al. 2014) , suggesting that folding stability prediction methods can prioritize candidate disease drivers (Bocchini et al. 2016; Pey et al. 2007; Siekierska et al. 2012 ) for chaperone treatment (Chaudhuri and Paul 2006) . However, these methods are partially limited by the availability of protein structure data. Although the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) currently contains more than 50,000 human protein structures, many are redundant and 30% of the human proteins have no PDB structure that corresponds to their sequence or any homologous sequence with as low as 30% sequence identity (Somody et al. 2017) . Alternatively, stability prediction methods may take advantage of the recent development of high-quality protein structure predictors, such as AlphaFold (Jumper et al. 2021) and RosettaFold (Baek et al. 2021) , which broaden the available number of protein structures. However, evolution-based stability prediction methods have competitive performance, despite the fact they do not use any structure information (Fariselli et al. 2015; Montanucci et al. 2019) .

Toward broader genome interpretation of variant effect, other prediction methods rely on protein sequence homology primarily, supported when available by function annotations and structural information. Table 1 lists well-established representatives of these methods, grouped according to the type of input data they use and whether the input includes scores from available predicting methods (Ensemble). Homology-based methods hypothesize that the frequent substitutions across clades are benign, under the implied assumption that homologous proteins share identical functions. Inversely, substitutions that do not occur across phylogenetic branches indicate negative selection and possible pathogenicity (Ng and Henikoff 2001) . To overcome limitations that stem from this hypothesis, homology-based prediction methods employ Baugh et al. 2016; Bendl et al. 2014 Bendl et al. , 2016 Bromberg and Rost 2007; Calabrese et al. 2009; Capriotti et al. 2013 Capriotti et al. , 2006 Carter et al. 2013; Chennen et al. 2020; Choi et al. 2012; Chun and Fay 2009; Dong et al. 2015; Gonzalez-Perez and Lopez-Bigas 2011; Gray et al. 2018; Gulko et al. 2015; Hecht et al. 2015; Ioannidis et al. 2016; Ionita-Laza et al. 2016; Jagadeesh et al. 2016; Kircher et al. 2014; Li et al. 2009 Li et al. , 2020 Munro and Singh 2020; Henikoff 2001, 2003; Niroula et al. 2015; Olatubosun et al. 2012; Pei et al. 2020; Pejaver et al. 2020; Ponzoni et al. 2020; Qi et al. 2021; Quang et al. 2015; Quinodoz et al. 2022; Raimondi et al. 2016 Raimondi et al. , 2017 Ramensky et al. 2002; Reva et al. 2011; Rogers et al. 2018; Samocha et al. 2017; Schwarz et al. 2010; Shihab et al. 2013 Shihab et al. , 2014 Shihab et al. , 2015 Stone and Sidow 2005; Sundaram et al. 2018; Takeda et al. 2020; Tavtigian et al. 2006; Thomas et al. 2003; Vaser et al. 2016; Yue et al. 2005 (Garber et al. 2009; Rogers et al. 2018; Shihab et al. 2013 Shihab et al. , 2015 Siepel et al. 2005; Thomas et al. 2003) , similarity scores (Choi et al. 2012) , normalized probabilities in localized sequence segments (Capriotti et al. 2006) , and restricting sequence alignments to mostly orthologous proteins (Mathe et al. 2006 ). These homology-based prediction methods are different from methods of residue importance (see a selected list in Table 2 ), which provide a "conservation" score for each protein residue rather than for each amino acid substitution.

To further improve variant effect predictions, additional insights into molecular functions (Calabrese et al. 2009 ) and physicochemical characteristics (Stone and Sidow 2005) can be considered, posing the problem of how to weigh the contributions of heterogeneous information sources. For this reason, machine learning techniques are routinely used to select and combine the numerous features that may indicate pathogenic or benign effects. Developers may select different techniques that work best for their purpose, including Support Vector Machines (Kircher et al. 2014; , Random Forests and other Decision Trees Raimondi et al. 2016 Raimondi et al. , 2017 Ramensky et al. 2002; Zhou et al. 2018a Some methods pool pre-existing prediction methods to estimate the protein function effects of variants with better accuracy. In Table 1 , we labeled as "Ensemble" the meta-methods that combine multiple pre-existing methods to obtain a single overall protein function impact score. Machine-learning approaches are typically used for such purposes. However, some of these methods have used preexisting prediction method scores together with additional features in their training, so we labeled them as "Ensemble + ". The method DANN (Quang et al. 2015) used the same feature set and training data as the method CADD (Kircher et al. 2014 ), but a different learning approach, and we subsequently labeled it "Ensemble + ". Figure 1 reflects the popularity for a large collection of available methods, indicated by the citations of the original articles as a function of the publication year.

In view of this diversity and importance of variant impact prediction methods, several reviews discuss the most common tools for predicting pathogenic variations, focusing on their underlying principles ( Hoskins et al. 2017 ) are critical to define appropriate use cases for each method, to set expectations for accuracy, and to evaluate performance improvements due to methodological refinements. Together Table 2 Predictors of residue importance Methods citations (Armon et al. 2001; Davydov et al. 2010; Garber et al. 2009; Glaser et al. 2003; Lichtarge et al. 1996; Mihalek et al. 2004; Pollard et al. 2010; Pupko et al. 2002; Siepel et al. 2005; Sunyaev et al. 1999 

Most methods estimate variant impact by weighing homology and/or structural information in unique ways. Homology-based predictors use multiple sequence alignments (MSA) to achieve their goal, which may either be narrow sets of orthologous sequences or larger sets that include distant homologs and paralogs. The choice of MSA affects the performance of the prediction methods and using the MSA provided by each method does not guarantee optimal performance (Hicks et al. 2011) . MSA are also useful in predictors that go beyond basic homology and infer additional properties. Distinct properties are captured by conservation scores (Sunyaev et al. 1999) , phylogenetic correlations of residues (Lichtarge et al. 1996) , amino acid substitution frequency (Henikoff and Henikoff 1992) , biochemical properties at the position of interest (Grantham 1974 ) and whole substitution profiles. These properties may define the context in which the mutation is observed, together with protein structure variables when a protein structure is available. (Hendlich et al. 1997; Yang et al. 2013) provide insights into changes occurring in the protein that can only be minimally inferred by homology-based methods. Given the plethora of features to choose and combine, differences between variant impact predictors are not surprising. In addition, many methods make use of various training data to refine predictions and select the most important features. The type of data chosen to train a method will likely influence the predicted impact to be more relevant to experimental, clinical, or evolutionary effects.

To validate, benchmark, and compare methods, predictors may turn to the experimental outcomes of large mutagenesis studies. For this purpose, four readily accessible datasets gained special popularity and were frequently used: (i) the repression activity of 4041 lac repressor mutations in E. coli (Markiewicz et al. 1994) , (ii) the transactivation activity of 2314 human p53 mutations (Kato et al. 2003) , When methods could be matched to multiple primary papers or newer versions were introduced, the paper with the most citations was used here. Methods are classified as (i) analytical models not trained on available variant annotations (red color), (ii) machine learning approaches trained on variant annotations (blue color), (iii) ensemble models that integrate scores from available predictors (purple color), and (iv) models that combine scores from available predictors and additional features (black color) (iii) the break-up of the host cell walls due to 2015 lysozyme mutations in bacteriophage T4 (Rennell et al. 1991) , and (iv) the cleavage of Gag and Gag-Pol due to 336 HIV-1 protease mutations (Loeb et al. 1989 ). More broadly, some dedicated databases curate experimental variation data for benchmarking (Kawabata et al. 1999; Sasidharan Nair and Vihinen 2013) . In addition, many more large mutagenesis studies are now available and could be used for additional benchmarking (Gray et al. 2017; Livesey and Marsh 2020; . Overall, variant impact prediction methods using these large datasets perform well, if not superbly, according to developer benchmark analyses. Pearson's correlations were nearly perfect when the experimental data were binned , showing excellent agreement with the overall trend despite point-by-point fluctuations. Accuracy was about 70% for SNAP (Bromberg and Rost 2007), 68-80% for SIFT (Ng and Henikoff 2001) , and slightly better for MAPP (Stone and Sidow 2005) . Areas under the ROC curve (AUC) have been reported to be 81-87% for PROVEAN (Choi et al. 2012 ) and from 86 to 89% for Evolutionary Action .

For further training and validation, prediction methods can also call upon databases of clinical annotations. A wellknown source of clinical associations is the ClinVar repository which reports associations between genetic variation and clinical phenotypes (Landrum et al. 2018) . Variants in this database were found in patient samples and annotated according to the guidelines of the American College of Medical Genetics (ACMG) and of the Association for Molecular Pathology (AMP) , with the goal to provide clinicians with the most robust consensus assessment. The ClinGen group convened Variant Curation Expert Panels to validate genetic annotations for specific genes or sets of genes and update variant annotations in ClinVar Rivera-Munoz et al. 2018 ). An alternative dataset that is frequently used in training variant impact predicting methods is the Human Gene Mutation Database (HGMD) (Stenson et al. 2020) . HGMD is a manually curated, proprietary collection of published germline mutations in nuclear genes associated with human inherited disease. Also, HumSavar is an open access collection of missense variant reports, curated from literature according to ACMG/AMP guidelines , and it is available through UniProtKB/Swiss-Prot (Wu et al. 2006 (Kroos et al. 2008) , Wilson disease , and others (Gout et al. 2007; Peltomaki and Vasen 2004) . The mouse-specific database Mutagenetix (Wang et al. , 2015 also contains genotype-phenotype correlations, using various phenotype assays. Using these databases, many studies showed that the disease driver variants are strongly enriched for pathogenic predictions. Performance, however, varies with the choice of reference dataset and the confidence level of the clinical association, and typically ranges between AUCs of 70% and 90% (Choi et al. 2012; Dong et al. 2015; Ioannidis et al. 2016; Niroula et al. 2015; Pejaver et al. 2020; Qi et al. 2021) . Nearly perfect AUCs are occasionally reported (Alirezaie et al. 2018; Ghosh et al. 2017 ), but such outstanding performances may be overly optimistic and prone to indirect circularity (Grimm et al. 2015) . The underlying hypothesis is that human polymorphisms have been under negative selection pressure that may eliminate or prevent the spread of many pathogenic variants. Therefore, most of the observed variants, especially those with high allele frequency should have nearly neutral or positive effects on protein function (Kimura 1979) . Prediction scores that were not trained on human polymorphisms supported this hypothesis, showing that human polymorphisms were enriched in low pathogenicity scores, with the enrichment becoming stronger for variants with higher minor allele frequency . Another study used VEST to show that sources based on complete genomes, such as The 1000 Genomes Project, contain less pathogenic-predicted variants than sources of compiled clinical data, such as Swis-sProt ). However, pathogenic variants exist within clinical genomes and studies suggest that predictors of protein function effects can prioritize them to identify candidate disease variants (Chennen et al. 2020; Ioannidis et al. 2016; Jagadeesh et al. 2016 ).

The performance of variant impact prediction methods is hard to assess unambiguously. Independent studies (Chan et al. 2007 ; (Zhang et al. 2019 (Zhang et al. , 2017a . Critically, all CAGI challenges use new and unpublished data, developer groups make predictions blind to pathogenic associations, and independent judges use multiple criteria to score success blind to the developer identity. The aims of these challenges are to recognize advantageous strategies used by the developers and bottlenecks that prevent the field from advancing. This goal is achieved through direct comparison of each method's performance and the features they use. In our view, the performance on the CAGI challenges did not point to obvious links between the type of predictor and the type of challenge, because it was subject to several cofounding factors (including input data availability, participation, predictor adjustments and approximations, assessor choices, assay or clinical data interpretation). Some methods clearly performed better than others according to multiple assessment metrics, but often different metrics indicated different top methods for the same challenge, highlighting the need for combining multiple metrics. Consistently top-ranked predictions come from the Evolutionary Action ( . It is worth noting that many less well-known participating methods showed better performance than PolyPhen2 and SIFT, which are very popular and widely used variant impact prediction methods . Very simple predictive models, such as baseline sequence conservation predictors, may perform on par or better than sophisticated methods (Zhang et al. 2019 (Zhang et al. , 2017a . Also, for a given approach (submissions from the Yang & Zhou lab on the cell proliferation rates upon CDKN2A variants), gradually adding features to the prediction model led to gradual performance improvements , indicating that future development should focus on the aggregation, refinement, and validation of new features. In the PCM1 challenge that evaluated 38 human missense mutations implicated in schizophrenia with a zebrafish model assay ), all submitted predictions had poor performance and yielded a nearly random distribution of balanced accuracy , leaving questions about the source of disagreement ). In the CALM1 gene challenge, the performance of all submitted predictions improved when the yeast complementation assay data points were limited to those with gradually smaller experimental standard deviation (Katsonis and Lichtarge 2019), indicating a potential underestimation of the performance in CAGI challenges due to experimental errors. In addition to these variant-level challenges, exome-level CAGI challenges have suggested that variant effect prediction methods can help in finding the disease risk of individuals (Cai et al. 2017; Chandonia et al. 2017; Daneshjou et al. 2017 ). However, addressing such challenges requires weighing the contribution of genes to each trait and combining the effects of multiple variants, which are not straightforward, so the successes were limited. Three CAGI challenges were related to predicting the risk of Crohn`s disease, with two of them resulting in unreliable performance evaluations due to sample stratification issues and the third one showing AUCs of up to 0.7 ). The performance was slightly worse for predicting the risk for venous thromboembolism, with AUCs up to 0.65 and accuracies up to 0.63 (McInnes et al. 2019 ). In a more complex challenge, two methods performed significantly better than chance for matching the clinical descriptions of undiagnosed patients (Kasak et al. 2019b ). However, it proved harder to distinguish between individuals of different intellectual disability phenotypes . Overall, predicting the risk of individuals for complex diseases remains challenging and methods predicting variant effect may complement current efforts to solve the etiology of more cases.

The methods predicting variant impact are already used in numerous practical applications, as indicated by the thousands of citations of PolyPhen2 (Adzhubei et al. 2010), SIFT (Kumar et al. 2009 ), and CADD (Kircher et al. 2014) , amongst other methods. Typically, they are used to assess the impact of new variants of unknown significance, narrow down driver candidates, and to support evidence for pathogenic effects. The ACMG and AMP guidelines encourage using multiple lines of computational evidence to support pathogenic or benign classification . In addition, variant impact prediction methods have been used to guide mutagenesis studies and associate genes to phenotype. Next, we discuss representative practical applications of predicting methods that illustrate their value in genome interpretation. Although these applications regard specific predicting methods each, the CAGI experiments suggest that other methods could be equally or more successful in addressing the same scientific questions.

Targeted mutagenesis experimental studies can take advantage of the variant impact predicting methods to reduce experimental cost and effort while maximizing return without missing key results (Sruthi and Prakash 2020). However, such applications are rare and typically complement other prioritization strategies that account for the available protein structures and methods that predict protein residue importance, such as the methods in Table 2 . For example, evolutionarily important residues were used to identify functional motifs in the DNA-dependent protein kinase catalytic subunit and the analysis of variant impact unveiled functional insights and implications (Lees-Miller et al. 2021 ). Variant effect prediction methods indicated human NAGK polymorphisms that reduced its binding to the dynein subunit DYNLRB1, an interaction that promotes cellular growth and other functions (Dash et al. 2021) . Mutation impact and important residues also guided mutagenesis studies aiming to uncover the interaction between the RecA and LexA protein in E. coli, which controls antibiotic resistance (Adikesavan et al. 2011; Marciano et al. 2014) . In G-proteincoupled receptors, variant impact scores correlated with the phenotypic change Schonegge et al. 2017) , and they were used in selecting targeted mutations that recode the allosteric pathway specificity (Peterson et al. 2015; Rodriguez et al. 2010; Schonegge et al. 2017 ). More recently, variant impact score analysis guided the development of a mutant esterase that gained stereospecificity properties while maintaining a 53-substrate repertoire (Cea-Rama et al. 2021) . These examples show that variant effect prediction methods can effectively prioritize and reduce the workload of mutagenic experimental studies. (Oluwole et al. 2020) , and Alzheimer's disease (Vardarajan et al. 2015) . Similar analyses for somatic mutations in tumors revealed strong selection patterns, either on numerous candidate genes (Bailey et al. 2018) or on specific genes such as in PTPN12 (Nair et al. 2018) , BAP1 (Sharma et al. 2019) , and TP53 . Therefore, computational approaches can prioritize somatic variants for their role in cancer, using variant effect predictors and gene features (Kaminker et al. 2007) . Predicting methods may also prioritize germline variants of trait-associated genes for further examination, such as in cardiovascular diseases (Rababa'h et al. 2013; Suryavanshi et al. 2018; Wang et al. 2021b) . With the spread of SARS-CoV-2, computational prediction methods have presented a functional site overview for all SARS-CoV-2 proteins (Wang et al. 2021a ) and suggested that their mutational hotspots can alter protein stability and binding affinity (Teng et al. 2021; Wu et al. 2021; Zou et al. 2020) . These studies show that predicting methods have practical value in a variety of clinical associations, in both Mendelian and complex diseases, including cancer.

Variant impact predictors may extend from the bench to the bedside. First tier clinical tests typically use chromosomal microarrays, with reported diagnostic yield of 15-20% in patients with developmental disabilities or congenital anomalies (Miller et al. 2010) . Unexplained cases may proceed to whole exome sequencing (WES) or whole genome sequencing (WGS) to fill this gap. Variant impact predictors can aid in the interpretation of the sequenced variants, offering significant increase in diagnostic yield (Grunseich et al. 2021; Stavropoulos et al. 2016) . Pharmacogenomics studies may take advantage of predicting methods to interpret the impact of amino acid variations on drug metabolism (Isvoran et al. 2017; Matimba et al. 2009 ). Additionally, the predicted pathogenicity of somatic mutations in cancer was used in a classification system that may inform patient management (Sukhai et al. 2016) . In a study of how TP53 variants affect the health of head and neck cancer patients, Evolutionary Action was able to stratify the overall survival and time to metastasis (Neskey et al. 2015) , indicated resistance to cisplatin therapy (Osman et al. 2015b) , and provoked suggestions for personalized treatment (Osman et al. 2015a) . Similarly, survival stratification was obtained in two independent studies for colorectal liver metastases patients (Chun et al. 2019 ) and myelodysplastic syndrome patients (Kanagal-Shamanna et al. 2021) . Therefore, predicting methods contribute in clinical diagnosis and can open paths toward precision medicine.

Variant impact scores may lead to associations of genes to traits. Typically, gene-trait associations rely on detecting selection patterns within a group of individuals who share the trait (cases) compared to unaffected individuals (controls). These selection patterns arise because trait driver genes harbor several pathogenic variants in cases, in addition to non-pathogenic variants that may appear in either the cases or the controls. Current gene discovery methods may quantify patterns such as whether the gene has more mutations compared to the expected number (Lawrence et al. 2013) , the mutations cluster in the protein structure or sequence compared to homogeneous spread (Tamborero et al. 2013) , and the characteristic nucleotide context of the mutations differs from the context of all other mutations (Dietlein et al. 2020) . Since the driver variants have larger predicted pathogenicity values compared to random nucleotide substitutions, methods that predict protein function effects offer an additional pattern toward pointing to candidate trait-driver genes. This selection pattern is orthogonal and complementary to the aforementioned measures, making variant impact prediction methods valuable for gene discovery. Next, we note such applications to somatic, de novo, and inherited variants.

Many cancer studies use variant impact prediction methods either as supporting evidence for the pathogenicity of gene variants (Bailey et al. 2018; Cancer Genome Atlas Research Network 2011) or as the main evidence to establish a genecancer link through an automated discovery process (Davoli et al. 2013; Gonzalez-Perez and Lopez-Bigas 2012; Hsu et al. 2022; Parvandeh et al. 2022) . The underlying hypotheses are that most somatic mutations are passengers (i.e. they do not contribute to oncogenesis) and that driver mutations (i.e. they contribute to the development of cancer) occur selectively in specific genes (Greenman et al. 2007; Stratton et al. 2009 ). Because the driver variants affect protein function, predicting methods should statistically score driver variants as more pathogenic than passenger variants (Carter et al. 2009; Chen et al. 2020; Cline et al. 2019; Mullany et al. 2015; Reva et al. 2011 ) and point to cancer driver genes. Moreover, protein effect prediction methods can inform regarding the role of each gene in cancer, with tumor suppressor genes having mostly loss-of-function variants with high impact scores and oncogenes having mostly gain-offunction variants with intermediate to high scores Shi and Moult 2011) . Gene pathway information may complement variant impact prediction methods in finding cancer driver genes (Cancer Genome Atlas Research Network 2017), even for small patient sets, such as 29 patients with sporadic Parathyroid Cancer (Clarke et al. 2019) . These applications suggest that variant impact prediction methods can help in finding candidate driver genes within whole cancer cohorts and within their cancer type divisions.

Variant impact prediction methods are commonly used in prioritizing the functional effects of de novo variants (Hu et al. 2016; Pejaver et al. 2020; Willsey et al. 2017 ). However, de novo variants are typically absent from the general population, with each individual harboring less than two coding de novo variants (Iossifov et al. 2012; Sevim Bayrak et al. 2020) . This fact limits the gene-level analysis of de novo variants, even for large datasets, such as the Simons Simplex Collection (SSC) (Fischbach and Lord 2010), which contains sequencing data from more than 2500 families with at least one child diagnosed with autism spectrum disorder (ASD) (Iossifov et al. 2012; Lord et al. 2020 Lord et al. , 2018 . Typically, such data are analyzed in the contexts of known gene-phenotype associations and the human interactome network . Variant impact prediction methods, such as MutPred2 (Pejaver et al. 2020) and VIPUR (Buja et al. 2018) , have shown that de novo variants in ASD cases have a higher fraction of predicted pathogenic variants compared to healthy siblings. Going one step further, a study using the Evolutionary Action (EA) method and gene pathway information without prior knowledge of phenotype associations identified 398 genes (representing 23 pathways) as candidate drivers for ASD, based on the enrichment of de novo variants to pathogenic scores (Koire et al. 2021) . The same study proposed polygenic risk scores based on the EA scores of either de novo or rare inherited variants on candidate genes and showed that these scores correlated with the Intelligence Quotient (IQ) of patients. These correlations were stronger when the contribution of each gene was weighted by Residual Variation Intolerance Scores (RVIS), a measure of genic intolerance to mutations (Petrovski et al. 2013) . Similar analyses can be done for more phenotypes, such as congenital heart disease (Jin et al. 2017) , where cases appear to have a higher fraction of predicted pathogenic variants compared to healthy controls (Qi et al. 2021) . Such large family datasets provide de novo mutations that can use variant impact predictions together with other information to discover new genes toward decoding the genotype-phenotype relationship.

Case-control studies are routinely designed for the discovery of genes associated with a particular trait. For Mendelian traits, these associations are straightforward, and methods predicting protein function effects can help Hu et al. 2013) . For complex traits, the standard is gene-based GWAS for the trait of interest using all variants within a gene rather than each variant individually (Huang et al. 2011; Liu et al. 2010 ), but phenome-wide association studies can also serve the same purpose (Denny et al. 2010). However, spurious associations resulting from correlations with the true risk factors can lead to false-positive results (Risch 2000) . Mendelian randomization may be used to overcome confounding (Grover et al. 2017 ) and complementary analyses including, but not limited to, literature textmining (Bhasuran and Natarajan 2018; Zhou and Fu 2018) and gene co-expression analyses (van Dam et al. 2018) can also help. Additionally, variant impact predictors can aid in deprioritizing variants predicted to have low functional impact, thus reducing such false positive discoveries (Lee et al. 2014; Wei et al. 2011) . For example, FATHMM-XF, SIFT, PolyPhen2, and CADD were used to prioritize 190 candidate genes for driving neuroticism (Belonogova et al. 2021) and similarly for other traits (Bacchelli et al. 2016; Zhang et al. 2018) . In CAGI challenges, many participants predicted the risk of individuals based on genomic data and matched genotypes to phenotypes better than random (Kasak et al. 2019b; Katsonis and Lichtarge 2019; Pal et al. 2017 Pal et al. , 2020 Wang and Bromberg 2019) . The imputed Deviation in Evolutionary Action Load (iDEAL) approach used protein function predictions to discover trait drivers (Kim et al. 2021) . Specifically, it was applied to late-onset Alzheimer's disease (AD) patients that paradoxically carried the ADprotective APOE ɛ2 allele compared to healthy individuals that carried the AD-risk APOE ɛ4 allele. This study identified 216 genes with differential Evolutionary Action load between the two populations. These genes showed a robust predictive power even in the independent set of APOE ɛ3 homozygote individuals and are potential drug targets. Therefore, there is strong evidence that methods predicting protein function effects have the potential to help in genome interpretation of complex diseases in a post-GWAS era.

This review of current computational estimates of protein function effects due to variants illustrates several practical applications. They routinely guide experimental studies of protein structure and function and clinical studies of variants of unknown significance that are candidate disease drivers. Most recently, they played a major role in identifying new genes associated with traits, for either somatic, de novo, or inherited variants. This ability to translate genomic data into quantitative traits raises hope for improved diagnostic tests with polygenic risk scores that account for functional effects rather than relying only on observational statistics. A caveat is that the basis for most methods remains rooted in homology information. The scores will thus tend to assess longterm "evolutionary" effects. Generally, and depending on the prediction method and the test data, these effects will tend to align with clinical or experimental impact as shown by strong correlations through extensive validation studies and objective assessments. In other words, the fitness landscape may appear similar at different scales.

In the past, variant impact prediction methods sustained pointed criticism (Flanagan et al. 2010; Mahmood et al. 2017; Tchernitchko et al. 2004 ) and this curtailed their use as prognostic tools. Most often, the criticism was fed on the one hand by a demand for nearly perfect accuracy in clinical diagnostics (Walters-Sen et al. 2015) , and on the other hand by disagreements, first, between different methods (Chun and Fay 2009) , and second, between prediction methods and experimental data or clinical annotations (Mahmood et al. 2017; Miller et al. 2019) . At some degree, these discrepancies are due to misalignments between the hypotheses adopted by the method developers and the data analysts: a key is useful only when it is properly applied to the right lock. In the light of epistatic interactions, inaccuracy is expected for single variant estimations, since each individual has a unique genetic, epigenetic, and environmental background that may modify the impact of this variant. These factors may result in incomplete penetrance, where two individuals with the same genetic variant can have either benign or disease phenotype linked to that variant Waalen and Beutler 2009; Zlotogora 2003) . Predictors can explicitly capture residue dependencies between positions to improve accuracy (Hopf et al. 2017 ) and focused methods can detect covariation signals in multiple sequence alignments to identify residue pairs with epistatic effects (Jones et al. 2012; Morcos et al. 2011; Salinas and Ranganathan 2018; Shen and Li 2016) . However, most predictors of protein function effects provide estimates in a broader view, as when individual background effects are averaged out over cohorts of individuals, suggesting they are more informative in high-penetrance genes and disorders. Literally, homologybased prediction methods ignore the context and answer whether a specific variant is pathogenic in an "evolutionary sense," which at best matches the human population at large rather than addressing the context-dependent effects of the variants (DiGiammarino et al. 2002) . The choice of a multiple sequence alignment input defines the "average context" of the computation and its potential biases and errors will affect the accuracy of the predictions (Hicks et al. 2011) . Each algorithmic approach weighs input features differently from the other methods, which may influence prediction accuracy dramatically. Since both the sequence alignment input and the algorithmic approach affect prediction accuracy, we should avoid generalizing the performance conclusions based on a single analysis. Moreover, the assessors should ensure their hypothesis does not conflict those underlying each prediction method. The CAGI challenges offer useful insights into the performance of different methods since method developers are able to modify their approach according to the needs of each challenge and independent assessors ensure objectivity. These assessments demonstrate progress in the field of variant impact prediction and the need to adjust predictors given specific tasks. Newer approaches achieve strong correlations with experimental assay data and perform consistently better than well-known methods (Katsonis and Lichtarge 2017). Such correlations may improve when the impact of experimental noise is reduced, using only data points with small standard deviations or combining multiple experimental assays . This suggests that even systematic assessments may under-estimate the performance of predicting methods.

Whole genome sequencing shows that non-synonymous variants are less than 0.3% of the total calls (Shen et al. 2013 ). There is therefore growing interest in prediction methods of other variant types. Stop-gain and frameshift insertion and deletion (fs-indel) variants result in protein sequence truncation and are traditionally viewed as pathogenic, but many of them appear frequently in human genomes even in a homozygous state (MacArthur and Tyler-Smith 2010). Non-frameshifting insertion and deletion (indel) variants are also of interest due to their link to diverse clinical effects and their substantial genetic load in most humans (Mullaney et al. 2010) . Methods such as SIFT Indel (Hu and Ng 2012) , DDIG-in (Folkman et al. 2015) , VEST-Indel (Douville et al. 2016) , and MutPred-LOF/-Indel (Pagel et al. 2017 may use homology, structure, intrinsic disorder predictions, and gene importance features to prioritize nonsense and indel variants with reported balanced accuracy of 80-90% (Douville et al. 2016) . PROVEAN (Choi et al. 2012 ) and MutationTaster2 (Schwarz et al. 2014 ) also provide predictions to non-frameshifting indel variants following the same framework they used for predicting the impact of missense variants. CADD (Kircher et al. 2014 ) is designed to predict the impact of all classes of genetic variation, including splice sites (Rentzsch et al. 2021 ) and non-coding variations. Methods that focus on predicting splicing effects use as input the genomic sequence of the pre-mRNA transcripts and include SpliceAI (Jaganathan et al. 2019) , MutPred Splice (Mort et al. 2014 ), Human Splicing Finder (Desmet et al. 2009 ), SPiCE (Leman et al. 2018) , and Skippy (Woolfe et al. 2010) . Methods that focus on predicting noncoding variant effects rely on functional genomics data, such as various sequence conservation and constraint scores (Dousse et al. 2016; Garber et al. 2009; Siepel et al. 2005) , in silico predictions of transcription factor binding sites, enhancer regions, and long noncoding RNAs (lncRNAs) (Abugessaisa et al. 2021; Fu et al. 2014; Loots and Ovcharenko 2004; Pachkov et al. 2013) , and experimental evidence provided by the Encyclopedia of DNA Elements (ENCODE) (Davis et al. 2018; Encode Project Consortium 2012) , including transcription factor ChIP-seq, DNA methylation arrays, and small RNAseq projects. Some non-coding functional impact predictors include, but are not limited to, LINSIGHT (Huang et al. 2017b) , GenoCanyon (Lu et al. 2015) , FATHMM-MKL (Shihab et al. 2015) , FATHMM-XF (Rogers et al. 2018) , PAFA (Zhou and Zhao 2018) , DIVAN , and GWAVA (Ritchie et al. 2014) . Synonymous variants, despite often assumed to be benign, are implicated in many diseases (Zeng and Bromberg 2019) . SiVA (Buske et al. 2013) , TraP (Gelfman et al. 2017) , DDIG-SN (Livingstone et al. 2017) , regSNPs-splicing (Zhang et al. 2017b) , IDSV , and synVep (Zeng et al. 2021 ) have used conservation, RNA, DNA, splicing, and protein features to prioritize synonymous variants with typical performances of 0.85-0.90 AUC (Zeng and Bromberg 2019) . Although we still need to objectively assess these methods, they may be useful for a transition to whole-genome interpretation.

Genome interpretation relies on the classification of genetic variants as pathogenic or benign, which necessitates the estimation of impact for all single variants. Clinical associations and experimental data are too limited for characterizing all variants, since more than 98% of the variants in human exomes have frequency of less than 1% (Karczewski et al. 2020; Van Hout et al. 2020 ) and over 40% of the ClinVar entries are catalogued as variants of unknown significance (Henrie et al. 2018) . Protein function effect prediction methods have shown strong correlations with established associations and may be cautiously used to start bridging the gap in genome interpretation. With the advent of less costly sequencing technologies, clinicians can read patient's genomes and search for precise therapies tailored to the genetic etiology of the disease. The insights provided by variant impact prediction methods may assist clinicians in selecting beneficial treatments. 

0: predicting stability changes upon mutation from the protein sequence or structure

Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information

A three-state prediction of single point mutations on protein stability changes

Collective judgment predicts disease-associated single nucleotide variants

Analysis of genetic variation and potential applications in genome-scale metabolic modeling

Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI

Assessment of patient clinical descriptions and pathogenic variants from gene panel sequences in the CAGI-5 intellectual disability challenge

Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations

Identifying Mendelian disease genes with the variant effect scoring tool

Congruency in the prediction of pathogenic missense mutations: state-of-the-art web-based tools

Structure and evolutionary trace-assisted screening of a residue swapping the substrate ambiguity and chiral specificity in an esterase

Inferring the effect of genomic variation in the new era of genomics

Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR)

Lessons from the CAGI-4 Hopkins clinical panel challenge

Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structurebased assessment of amino acid variation

Protein-misfolding diseases and chaperone-based therapeutic approaches

DIVAN: accurate identification of noncoding disease-specific risk variants using multi-omics profiles

An interactome perturbation framework prioritizes damaging missense mutations for developmental disorders

Comprehensive assessment of computational algorithms in predicting cancer driver mutations

Prediction of protein stability changes for single-site mutations using support vector machines

MISTIC: A prediction tool to reveal disease-relevant deleterious missense variants

Predicting the functional effect of amino acid substitutions and indels

Identification of deleterious mutations within three human genomes

Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases

Assessment of predicted enzymatic activity of alpha-N-acetylglucosaminidase variants of unknown significance for CAGI 2016

The international genome sample resource (IGSR): A worldwide collection of genome variation incorporating the 1000 genomes project data

Comprehensive genomic characterization of parathyroid cancer identifies novel candidate driver mutations and core pathways

Using bioinformatics to predict the functional impact of SNVs

Selection and adaptation in the human genome

FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer

The post-GWAS Era: from association to function

Predicting phenotype from genotype: Improving accuracy through more robust experimental and computational modeling

HuVarBase: A human variant database with comprehensive information at gene and protein levels

Identifying novel constrained elements by exploiting biased substitution patterns

Annotating pathogenic non-coding variants in genic regions

Whole-genome sequence variation, population structure and demographic history of the Dutch population

The GenomeAsia 100K Project enables genetic discoveries across Asia

Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines

The evolving genetic risk for sporadic ALS

Crohn disease risk prediction-Best practices and pitfalls with exome data

ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information

Data integration in the era of omics: current and future challenges

Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel

Functional impact bias reveals cancer drivers

PKDB: polycystic kidney disease mutation database-a gene variant database for autosomal dominant polycystic kidney disease

Amino acid difference formula to help explain protein evolution

Analysis of large-scale mutagenesis data to assess the impact of single amino acid substitutions

Quantitative missense variant effect prediction using large-scale mutagenesis data

Stratton MR (2007) Patterns of somatic mutation in human cancer genomes

The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity

Mendelian randomization

Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases

Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations

A method for calculating probabilities of fitness consequences for point mutations across the human genome

Assessing performance of pathogenicity predictors using clinically relevant variant datasets

GenoPheno: cataloging large-scale phenotypic and next-generation sequencing data within human datasets

A review study: Computational techniques for expecting the impact of non-synonymous single nucleotide variants in human diseases

Better prediction of functional effects for sequence variants

LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins

Amino acid substitution matrices from protein blocks

Using substitution probabilities to improve position-specific scoring matrices

ClinVar Miner: Demonstrating utility of a Web-based tool for viewing and filtering ClinVar data

Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed

Mutation effects predicted from sequence co-variation

Reports from CAGI: The critical assessment of genome interpretation

A general calculus of fitness landscapes finds genes under selection in cancers

Predicting the effects of frameshifting indels

VAAST 2.0: improved variant classification and disease-gene identification using a conservation-controlled amino acid substitution matrix

VARPRISM: incorporating variant prioritization in tests of de novo mutation association

VIPdb, a genetic variant impact predictor database

Genebased tests of association

More Is better: recent progress in multi-omics data integration methods

Fast, scalable prediction of deleterious noncoding variants from functional and population genomic data

REVEL: an ensemble method for predicting the pathogenicity of rare missense variants

A spectral approach integrating functional genomic annotations for coding and noncoding variants

De novo gene disruptions in children on the autistic spectrum

Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism

M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity

Predicting splicing from primary sequence with deep learning

IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes

Korean Genome Project: 1094 Korean personal genomes with clinical information

CAGI SickKids challenges: Assessment of phenotype and variant predictions derived from clinical and genomic data of children with undiagnosed diseases

Understanding the function-structure and functionmutation relationships of p53 tumor suppressor protein by highresolution missense mutation analysis

A formal perturbation equation between genotype and phenotype determines the Evolutionary Action of protein-coding variations on fitness

Objective assessment of the evolutionary action equation for the fitness effect of missense mutations across CAGI-blinded contests

CAGI5: Objective performance assessments of predictions based on the Evolutionary Action equation

Single nucleotide variations: biological impact and theoretical interpretation

The protein mutant database

KoVariome: Korean national standard reference variome database of whole genomes with comprehensive SNV, indel, CNV, and SV analyses

Harnessing the paradoxical phenotypes of APOE varepsilon2 and APOE varepsilon4 to identify genetic modifiers in Alzheimer's disease

The neutral theory of molecular evolution

A general framework for estimating the relative pathogenicity of human genetic variants

Lichtarge O (2021) A method to delineate de novo missense variants across pathways prioritizes genes linked to autism

Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating

Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

WilsonGen a comprehensive clinically annotated genomic variant resource for Wilson's

Clin-Var: improving access to variant interpretations and supporting evidence

Mutational heterogeneity in cancer and the search for new cancer-associated genes

The interpretation of protein structures: estimation of static accessibility

Rare-variant association analysis: study designs and statistical tests

Uncovering DNA-PKcs ancient phylogeny, unique sequence motifs and insights for human disease

Analysis of protein-coding genetic variation in 60,706 humans

Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/ in vitro studies: an international collaborative effort

Assessment of the predictive accuracy of five in silico prediction tools, alone or in combination, and two metaservers to classify long QT syndrome gene mutations

Automated inference of molecular mechanisms of disease from amino acid substitutions

CanProVar: a human cancer proteome variation database

Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-offunction mutant p53(R172H)

Performance evaluation of pathogenicity-computation methods for missense variants

CAPICE: a computational method for Consequence-Agnostic Pathogenicity Interpretation of Clinical Exome variations

An evolutionary trace method defines binding surfaces common to protein families

Effects of short indels on protein structure and function in human genomes

A versatile gene-based test for genome-wide association studies

Biological relevance of computationally predicted pathogenicity of noncoding variants

Using deep mutational scanning to benchmark variant effect predictors and identify disease mutations

Investigating DNA-, RNA-, and protein-based features as a means to discriminate pathogenic synonymous variants

Complete mutagenesis of the HIV-1 protease

rVISTA 2.0: evolutionary analysis of transcription factor binding sites

Autism spectrum disorder

Autism spectrum disorder

A statistical framework to predict functional non-coding regions in the human genome through integrated analysis of annotation data

Loss-of-function variants in the genomes of healthy humans

The new NHGRI-EBI Catalog of published genomewide association studies (GWAS Catalog)

Variant effect prediction tools assessed using independent, functional assay-based datasets: implications for discovery and diagnostics

The NCBI dbGaP database of genotypes and phenotypes

Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa

The Simons Genome Diversity Project: 300 genomes from 142 diverse populations

Negative feedback in genetic circuits confers evolutionary resilience and capacitance

Parkinson's Progression Markers I (2018) The Parkinson's progression markers initiative (PPMI) -establishing a PD biomarker cohort

Changing haemodynamics in patient with papillary muscle dysfunction

Genetic studies of the lac repressor. XIV. Analysis of 4000 altered Escherichia coli lac repressors reveals essential and non-essential residues, as well as "spacers" which do not require a specific sequence

Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods

Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects

Predicting venous thromboembolism risk from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges

Determining the pathogenicity of CFTR missense variants: Multiple comparisons of in silico predictors and variant annotation databases

A family of evolution-entropy hybrid methods for ranking protein residues by importance

Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies

What went wrong with variant effect predictor performance for the PCM1 challenge

Comparison of predicted and actual consequences of missense mutations

Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes

DDGun: an untrained method for the prediction of protein stability changes upon single and multiple point variations

Performance of computational methods for the evaluation of pericentriolar material 1 missense variants in CAGI-5

Direct-coupling analysis of residue coevolution captures native contacts across many protein families

MutPred Splice: machine learningbased prediction of exonic variants that disrupt splicing

Small insertions and deletions (INDELs) in human genomes

Responses to nutlin-3a, and cell survival

DeMaSk: a deep mutational scanning substitution matrix and its use for variant impact prediction

Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer

Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

Predicting deleterious amino acid substitutions

SIFT: Predicting amino acid changes that affect protein function

PON-P2: prediction method for fast and reliable identification of harmful variants

PON-P: integrated predictor for pathogenicity of missense variants

Targeted next-generation sequencing identifies novel variants in candidate genes for Parkinson's disease in Black South African and Nigerian patients

From protein structure to function

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence

Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5)

SwissRegulon, a database of genome-wide annotations of regulatory sites: recent updates

When loss-of-function is loss of function: assessing mutational signatures and impact of loss-of-function genetic variants

Pathogenicity and functional impact of non-frameshifting insertion/deletion variation in the human genome

CAGI4 Crohn's exome challenge: Marker SNP versus exome variant models for assigning risk of Crohn disease

Matching whole genomes to rare genetic disorders: Identification of potential causative variants using phenotype-weighted knowledge in the CAGI SickKids5 clinical genomes challenge

CUPSAT: prediction of protein stability upon point mutations

EPIMUTESTR: a nearest neighbor machine learning approach to predict cancer driver genes from the evolutionary action of coding variants

The fixation probability of beneficial mutations

Mutation severity spectrum of rare alleles in the human genome is predictive of disease type

Missense variant pathogenicity predictors generalize well across a range of functionspecific prediction challenges

Inferring the molecular and phenotypic impact of amino acid variants with MutPred2

Mutations associated with HNPCC predisposition -Update of ICG-HNPCC/INSiGHT mutation database

Bioinformatics and computational tools for next-generation sequencing analysis in clinical genetics

Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization

Elucidation of G-protein and beta-arrestin functional selectivity at the dopamine D2 receptor

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Genic intolerance to functional variation and the interpretation of personal genomes

Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases

DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach

Synonymous but not the same: the causes and consequences of codon bias

Detection of nonneutral substitution rates on mammalian phylogenies

Rhapsody: predicting the pathogenicity of human missense variants

Linkage disequilibrium in humans: models and data

Rate4Site: an algorithmic tool for the identification of functional regions in proteins by surface mapping of evolutionary determinants within their homologues

MVP predicts the pathogenicity of missense variants by deep learning

STRUM: structure-based prediction of protein stability changes upon single-point mutation

DANN: a deep learning approach for annotating the pathogenicity of genetic variants

Analysis of missense variants in the human genome reveals widespread gene-specific clustering and improves prediction of pathogenicity

Protein kinase A and phosphodiesterase-4D3 binding to coding polymorphisms of cardiac muscle anchoring protein (mAKAP)

Multilevel biological characterization of exomic variants at the protein level significantly improves the identification of their deleterious effects

DEOGEN2: prediction and interactive visualization of single amino acid variant deleteriousness in human proteins

Human non-synonymous SNPs: server and survey

Clin-Gen-the clinical genome resource

Systematic mutation of bacteriophage T4 lysozyme

CADD-Spliceimproving genome-wide variant effect prediction using deep learning-derived splice scores

Predicting the functional impact of protein mutations: application to cancer genomics

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology

Searching for genetic determinants in the new millennium

Functional annotation of noncoding sequence variants

ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation

Evolutionguided discovery and recoding of allosteric pathway specificity determinants in psychoactive bioamine receptors

FATHMM-XF: accurate prediction of pathogenic point mutations via extended features

The NINDS Parkinson's disease biomarkers program

Coevolution-based inference of amino acid interactions underlying protein function

Regional missense constraint improves variant deleteriousness prediction

VariBench: a benchmark database for variations

Desmosterolosis-phenotypic and molecular characterization of a third case and review of the literature

Evolutionary action and structural basis of the allosteric switch controlling beta2AR functional selectivity

Muta-tionTaster evaluates disease-causing potential of sequence alterations

Mutation-Taster2: mutation prediction for the deep-sequencing age

De novo variants in exomes of congenital heart disease patients identify risk genes and pathways

Mutational landscape of the BAP1 locus reveals an intrinsic control to regulate the miRNA network and the binding of protein complexes in uveal melanoma

A novel algorithm for detecting multiple covariance and clustering of biological sequences

Comprehensive characterization of human genome variation by high coverage whole-genome sequencing of forty four Caucasians

Structural and functional impact of cancerrelated missense somatic mutations

Computational identification of deleterious synonymous variants in human genomes using a feature-based approach

Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models

An integrative approach to predicting the functional effects of non-coding and coding sequence variation

) alpha-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants

Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes

Structural coverage of the proteome for pharmaceutical applications

Prediction and assessment of splicing alterations: implications for clinical testing

Deep2Full: Evaluating strategies for selecting the minimal mutational experiments for optimal computational predictions of deep mutational scan outcomes

Toward Developing Intuitive Rules for Protein Variant Effect Prediction Using Deep Mutational Scanning Data

Whole genome sequencing expands diagnostic utility and improves clinical management in pediatric medicine

Molecular mechanisms of disease-causing missense mutations

The human gene mutation database (HGMD((R))): optimizing its use in a clinical diagnostic or research setting

Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity

The cancer genome

Multiomics data integration, interpretation, and its application

UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age

A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer

Utility of B-factors in protein science: interpreting rigidity, flexibility, and internal motion and engineering thermostability

Predicting the clinical impact of human mutation with deep neural networks

PSIC: profile extraction from sequence alignments with position-specific counts of independent observations

Human muscle-specific A-kinase anchoring protein polymorphisms modulate the susceptibility to cardiovascular diseases by altering cAMP/PKA signaling

Comparison of Pathogenicity Prediction Tools on Somatic Variants

InMeRF: prediction of pathogenicity of missense variants by individual modeling for each amino acid substitution

Oncodrive-CLUST: exploiting the positional clustering of somatic mutations to identify cancer genes

Tools for predicting the functional impact of nonsynonymous genetic variation

COSMIC: the catalogue of somatic mutations in cancer

Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral

In silico prediction of the deleterious effect of a mutation: proceed with caution in clinical genetics

Modeling effects of human single nucleotide polymorphisms on protein-protein interactions

Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity

A global reference for human genetic variation

The International Hap-Map Project

PANTHER: a library of protein families and subfamilies indexed by function

REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification

Intrinsically disordered proteins in human diseases: introducing the D2 concept

Gene co-expression analysis for functional classification and gene-disease predictions

Exome sequencing and characterization of 49,960 individuals in the UK Biobank

Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci

SIFT missense predictions for genomes

Assessing the performance of in silico methods for predicting the pathogenicity of variants in the gene CHEK2, among Hispanic females with breast cancer

Genetic screening for low-penetrance variants in protein-coding genes

Variability in pathogenicity prediction programs: impact on clinical diagnostics

Identifying mutation-driven changes in gene functionality that lead to venous thromboembolism

SNPs, protein structure, and disease

Real-time resolution of point mutations that cause phenovariance in mice

Probability of phenotypically detectable protein damage by ENU-induced mutations in the Mutagenetix database

De novo mutations from whole exome sequencing in neurodevelopmental and psychiatric disorders: from discovery to application

Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family

Rare, damaging DNA variants in CORIN and risk of coronary artery disease: Insights from functional genomics and large-scale sequencing analyses

Incorporating predicted functions of nonsynonymous variants into gene-based analysis of exome sequencing data: a comparative study

Comprehensive catalog of European biobanks

Tourette International Collaborative G, Tourette Syndrome Association International Consortium for

Genomic features defining exonic variants that modulate splicing

SDM-a server for predicting effects of mutations on protein stability and malfunction

The Universal protein resource (UniProt): an expanding universe of protein information

Effects of SARS-CoV-2 mutations on protein structures and intraviral protein-protein interactions

Benchmarking predictions of allostery in liver pyruvate kinase in CAGI4

In silico analysis for determining the deleterious nonsynonymous single nucleotide polymorphisms of BRCA genes

BioLiP: a semi-manually curated database for biologically relevant ligand-protein interactions

AWESOME: a database of SNPs that affect protein post-translational modifications

Silico Tools and Approaches for the prediction of functional and structural effects of single-nucleotide polymorphisms on proteins: an expert review

Ensemble variant interpretation methods to predict enzyme activity and assign pathogenicity in the CAGI4 NAGLU (Human N-acetyl-glucosaminidase) and UBE2I (Human SUMO-ligase) challenges

Identification and analysis of deleterious human SNPs

Loss of protein structure stability as a major causative factor in monogenic disease

SNPs3D: candidate gene and SNP selection for association studies

The role of protein structural analysis in the next generation sequencing era

Predicting functional effects of synonymous variants: a systematic review and perspectives

EFIN: predicting the functional impact of nonsynonymous single nucleotide polymorphisms in human genome

Decoding the effects of synonymous variants

Assessing predictions of fitness effects of missense mutations in SUMO-conjugating enzyme UBE2I

regSNPssplicing: a tool for prioritizing synonymous single-nucleotide substitution

Exome sequencing of a large family identifies potential candidate genes contributing risk to bipolar disorder

Assessing predictions on fitness effects of missense variants in calmodulin

The research on gene-disease association based on text-mining of PubMed

Prioritization and functional assessment of noncoding variants associated with complex diseases

Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction

ENTPRISE: An Algorithm for Predicting Human Disease-Associated Amino Acid Substitutions from Sequence Entropy and Predicted Protein Structures

ENTPRISE-X: Predicting disease-associated frameshift and nonsense mutations

Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data

Penetrance and expressivity in the molecular age

Computational prediction of mutational effects on SARS-CoV-2 binding by relative free energy calculations

Acknowledgements This work was supported by the National Insti-